Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jiri Vencovsky

Showing results (21-30 of 70) with videos related to

Pageof 7
Sort By:
Journal of the American Society of Hypertension : JASH|December 3, 2014
The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trialGeorge D Kitas, Gabriel Abreu, Krystyna Jedrychowicz-Rosiak, et al.
Neuromuscular Disorders : NMD|April 22, 2004
119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The NetherlandsJessica E Hoogendijk, Anthony A Amato, Bryan R Lecky, et al.
Heliyon|October 14, 2024
Deciphering miRNA signatures in axial spondyloarthritis: The link between miRNA-1-3p and pro-inflammatory cytokinesAneta Prokopcova, Jiri Baloun, Kristyna Bubova, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 10, 2023
Novel Somatic UBA1 Variant in a Patient With VEXAS SyndromeBlanka Stiburkova, Katerina Pavelcova, Monika Belickova, et al.
Arthritis Research & Therapy|September 17, 2015
Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritisJana Hurnakova, Jakub Zavada, Petra Hanova, et al.
Arthritis Research & Therapy|September 11, 2015
Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patientsJosef S Smolen, Ronald van Vollenhoven, Arthur Kavanaugh, et al.
Annals of the Rheumatic Diseases|May 31, 2011
Interrater reliability and aspects of validity of the myositis damage indexShabina M Sultan, Elizabeth Allen, Robert G Cooper, et al.
Plos One|November 11, 2016
Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical RemissionJana Hurnakova, Hana Hulejova, Jakub Zavada, et al.
Plos One|August 24, 2017
Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort studyJana Hurnakova, Hana Hulejova, Jakub Zavada, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 24, 2017
A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid ArthritisMichael E Weinblatt, Iain B McInnes, Joel M Kremer, et al.
Pageof 7

Showing results (21-30 of 70) with videos related to

Sort By:
Pageof 7
Journal of the American Society of Hypertension : JASH|December 3, 2014
The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trialGeorge D Kitas, Gabriel Abreu, Krystyna Jedrychowicz-Rosiak, et al.
Neuromuscular Disorders : NMD|April 22, 2004
119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The NetherlandsJessica E Hoogendijk, Anthony A Amato, Bryan R Lecky, et al.
Heliyon|October 14, 2024
Deciphering miRNA signatures in axial spondyloarthritis: The link between miRNA-1-3p and pro-inflammatory cytokinesAneta Prokopcova, Jiri Baloun, Kristyna Bubova, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 10, 2023
Novel Somatic UBA1 Variant in a Patient With VEXAS SyndromeBlanka Stiburkova, Katerina Pavelcova, Monika Belickova, et al.
Arthritis Research & Therapy|September 17, 2015
Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritisJana Hurnakova, Jakub Zavada, Petra Hanova, et al.
Arthritis Research & Therapy|September 11, 2015
Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patientsJosef S Smolen, Ronald van Vollenhoven, Arthur Kavanaugh, et al.
Annals of the Rheumatic Diseases|May 31, 2011
Interrater reliability and aspects of validity of the myositis damage indexShabina M Sultan, Elizabeth Allen, Robert G Cooper, et al.
Plos One|November 11, 2016
Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical RemissionJana Hurnakova, Hana Hulejova, Jakub Zavada, et al.
Plos One|August 24, 2017
Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort studyJana Hurnakova, Hana Hulejova, Jakub Zavada, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 24, 2017
A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid ArthritisMichael E Weinblatt, Iain B McInnes, Joel M Kremer, et al.
Pageof 7